首页   按字顺浏览 期刊浏览 卷期浏览 Megestrol Acetate in Advanced Breast Carcinoma
Megestrol Acetate in Advanced Breast Carcinoma

 

作者: Marc Espie,  

 

期刊: Oncology  (Karger Available online 1994)
卷期: Volume 51, issue 1  

页码: 8-12

 

ISSN:0030-2414

 

年代: 1994

 

DOI:10.1159/000227408

 

出版商: S. Karger AG

 

关键词: Hormonal treatment;Advanced breast cancer;Megestrol acetate

 

数据来源: Karger

 

摘要:

Hormonal therapy of breast cancer is the oldest treatment in advanced disease. Durable remissions can be obtained with a wide variety of hormonal manipulations. Oophorectomy was first used to reduce endogenous hormonal levels. Surgical procedures have been supplanted by drugs that reduce hormone secretion or block steroid hormone activity. Tamoxifen is the agent most widely used because of few side effects. Agonists can also be effective. Estrogens, androgens, and progestins have the same level of activity as surgical ablation or drug antagonists (20-40% overall response rate). More than 2,000 patients with advanced breast cancer worldwide have been treated with megestrol acetate in clinical trials. Reports of the trials show a response rate of 27%. In randomized trials, efficacy of megestrol acetate is comparable with tamoxifen and with other hormonal treatments. At the standard dose of 160 mg/day, the major side effect is weight gain. Studies are ongoing to evaluate if high doses of megestrol acetate may increase the response rate with acceptable toxicity.

 

点击下载:  PDF (2400KB)



返 回